BioLife Solutions, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
BioLife Solutions, Inc. (BLFS) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$9.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- BioLife Solutions, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$10.22M.
- BioLife Solutions, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$28.44M.
- BioLife Solutions, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$5.65M.
- BioLife Solutions, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$348.00K.
- BioLife Solutions, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$62.35M, a 204.00% decline from fiscal 2024.
- BioLife Solutions, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $59.95M, a 276.32% increase from fiscal 2023.
- BioLife Solutions, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $15.93M.
- BioLife Solutions, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$50.29M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.04M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$10.22M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$62.35M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$65.91M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$63.48M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$28.44M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $59.95M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | -$11.25M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$13.33M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$5.65M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $15.93M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | -$179.00K 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $1.93M 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | -$348.00K 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | -$50.29M 10-K · filed 2025-03-03 | |||
| 2022-09-30 | -$42.63M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$45.65M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | -$10.38M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$20.56M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | -$15.14M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | -$14.16M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | -$1.39M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $84.01M 10-K · filed 2023-03-31 | |||
| 2020-09-30 | $102.54M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $23.43M 10-Q · filed 2021-08-16 | |||
| 2019-12-31 | -$24.21M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B |